All In Biotech

Free tool

FAERS Monitor: Jelmyto

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211728 or its brand name (Jelmyto, Mitomycin). Reports on generic versions are filed under their own applications.

Reports

3,208

Serious

2,668

83% of reports

Hospitalization

987

Death reported

398

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use384
  • nausea165
  • diarrhoea158
  • fatigue118
  • thrombocytopenia112
  • vomiting111
  • neutropenia109
  • drug ineffective108
  • rash107
  • pancytopenia104
  • disease progression100
  • pyrexia95
  • death93
  • pain82
  • leukopenia76

Reports by year received

View as table
YearReports
200467
200577
200686
200796
2008125
200979
201094
2011137
2012134
2013129
201486
2015112
201697
201786
2018127
2019160
2020157
2021186
2022212
2023148
2024252
2025342
2026219

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,951 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pancytopeniaSignal10412.210.11,061
leukopeniaSignal7610.08.0605
thrombocytopeniaSignal1126.65.5526
disease progressionSignal1005.54.6370
neutropeniaSignal1095.34.4374
off label useSignal3842.92.6488
pyrexia951.81.534
rash1071.61.325
diarrhoea1581.61.437
vomiting1111.51.321
nausea1651.41.217
fatigue1181.00.80
pain820.90.71
death930.70.611
drug ineffective1080.50.445

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.